Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02405741
Recruitment Status : Unknown
Verified March 2015 by Assaf Harofeh MC, Assaf-Harofeh Medical Center. Recruitment status was: Recruiting
Hyperbaric chamber treatment assists in increasing the amount of oxygen in the plasma and in the tissues and has been proven to be beneficial in treating different ischemic wounds, and acute retinal artery occlusion (ARAO) but its effect hasn't been tested in CRVO patients yet.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients age 18-80 years with a documented CRVO who treated by Avastin for more than 12 months.
Patients who signed an informed consent form
Patients with Carotid stenosis of more than 70%
Anemia of < 10mg/Dl
Patients with chest X ray pathology which cannot be admitted to hyperbaric chamber treatment.
Patients with claustrophobia or that cannot decompress properly.